重组人血管内皮抑制素联合肝动脉栓塞化疗术治疗中晚期原发性肝癌的临床研究

目的：探讨重组人血管内皮抑制素联合肝动脉栓塞化疗术（TACE）治疗中晚期肝癌的临床疗效和不良反应，为治疗中晚期肝癌寻求有效的治疗手段。方法：选择我院2011年1月至2014年12月收治的中晚期肝癌患者62例，随机分为观察组32例和对照组30例。对照组给予TACE治疗；观察组在给予TACE治疗的基础上，联合肝动脉灌注恩度（重组人血管内皮抑制素注射液）治疗。治疗结束后观察和评价2组患者的临床疗效和不良反应的发生情况。结果：治疗后，对照组的有效率为46.67%，观察组的有效率为75.00%，观察组显著高于对照组（P＜0.05）；观察组的无进展生存时间（PFS）较对照组显著延长（P＜0.05），2组的生存时间（OS）差异无统计学意义（P＞0.05）； 2组不良反应发生率比较差异无统计学意义（P＞0.05）。结论：重组人血管内皮抑制素联合TACE治疗可以有效提高中晚期肝癌的临床疗效，延长PFS，且不增加不良反应，具有重要的临床价值。

Clinical study of recombinant human endostatin combined with hepatic arterial chemoembolization in advanced primary hepatic carcinoma

Objective: To investigate the clinical efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with transcatheter arterial chemoembolization (TACE) in advanced hepatocellular carcinoma (aHCC) and provide the reference treatment for aHCC. Methods: Sixty-two patients with advanced hepatocellular carcinoma were enrolled from January 2011 to December 2014 in our hospital which were divided randomly into observation group (32 cases) and control group (30 cases) according to the therapeutic methods, the patients of control group were treated with TACE, while the observation group was treated with TACE combined with hepatic dynamic arterial infusion of Endostar. The clinical efficacy and adverse reactions were observed and evaluated between two groups after treatment. Results: The effective rate of observation group was 75%, which was significantly higher than that of the control group with 46.67% (P<0.05), the PFS of observation group was significantly longer than the control group (P<0.05), the survival time was not significantly different (P>0.05) in two groups. No significant difference was found in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Endostar combined with TACE can effectively improve the clinical efficacy and prolong the PFS without more adverse reactions in aHCC, which has important clinical value.